The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Chuikyo Backs MHLW Proposal on Fertility Treatment Coverage
With the aim of introducing health coverage for fertility treatments from next April, the Ministry of Health, Labor and Welfare (MHLW) presented a proposal to a key reimbursement policy panel on December 15, saying that “drugs that have received regulatory…
To read the full story
Related Article
- 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
- Chuikyo Calls for Smooth Transition to Fertility Treatment Coverage from Current Subsidy System
November 18, 2021
- Japan to Discuss Approval of Individual Fertility Drugs after August
July 26, 2021
- Reproductive Medicine Society Issues Fertility Treatment Guidelines, Prods Careful Design for Health Coverage
June 25, 2021
- Chuikyo Receives Report on Fertility Treatment Survey, Awaits Guidelines to Discuss Coverage
April 16, 2021
REGULATORY
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…